Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.68 |
| ▸ | GPR52 | Q9Y2T5 | 5/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784220 | 0.93 | PDE4B (0.70) | PDE4BGPR52PDE4APDE4CPDE4D | |
| SCHEMBL17784215 | 0.91 | PDE4B (0.69) | PDE4BGPR52PDE4APDE4CPDE4D | |
| SCHEMBL17784222 | 0.88 | PDE4B (0.69) | PDE4BGPR52PDE4APDE4CPDE4D | |
| SCHEMBL17784231 | 0.87 | PDE4B (0.66) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL16446841 | 0.86 | PDE4B (0.67) | PDE4BGPR52PDE4APDE4CPDE4D | |
| SCHEMBL17784230 | 0.86 | PDE4B (0.83) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL17784229 | 0.83 | PDE4B (0.67) | PDE4BGPR52PDE4APDE4CPDE4D | |
| SCHEMBL17784218 | 0.82 | PDE4B (0.69) | PDE4BGPR52PDE4APDE4CPDE4D | |
| SCHEMBL16448339 | 0.81 | PDE4B (0.52) | PDE4BSMN1; SMN2MAPK9CDK8MAPK14 | |
| SCHEMBL17784214 | 0.78 | PDE4B (1.00) | PDE4BRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030565-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | PDE4B 2/4885GPR52 1370/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.